Details

Autor(en) / Beteiligte

• Lea, Jayanthi S.
• Sheets, Ellen E.
• Wenham, Robert M.
• Duska, Linda R.
• Coleman, Robert L.
• Miller, David S.
• Schorge, John O.

Titel

Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival

Ist Teil von

• Gynecologic oncology, 2002-01, Vol.84 (1), p.115-119

Ort / Verlag

San Diego, CA: Elsevier Inc

Erscheinungsjahr

2002

Quelle

Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Beschreibungen/Notizen

• Objective. The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB–IVB disease. Methods. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan–Meier survival estimates. Results. Eighty-three women with FIGO stage IIB–IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22–88). The median follow-up of 17 (20%) surviving patients was 33 months (range, 6–147); 66 (80%) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64% vs 8%) and 5 years (30% vs 0%) than women with stage IIIA–IVB disease (n = 42; P < 0.01). Conclusions. Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.